Marathon Sells Emflaza to PTC Therapeutics

11:21 EDT 20 Mar 2017 | CHEManager

US drugmaker Marathon Pharmaceuticals has sold all rights to its Duchenne muscular dystrophy (DMD) drug Emflaza (deflazacort) to PTC Therapeutics in a deal that could be potentially worth more than $190 million.

Original Article: Marathon Sells Emflaza to PTC Therapeutics


More From BioPortfolio on "Marathon Sells Emflaza to PTC Therapeutics"

Quick Search

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...